In a prior study, idalopirdine added to donepezil improved cognitive performance in patients with moderate Alzheimer disease (AD) dementia. To confirm or refute these initial findings, Atri and colleagues conducted 3 randomized trials in 2525 patients with mild to moderate AD and found that idalopirdine did not improve cognition over 24 weeks of treatment. In an Editorial, Bennett suggests that delaying the onset of dementia may have a greater impact on population health than treating AD once it has become symptomatic.
Highlights. JAMA. 2018;319(2):103–105. doi:10.1001/jama.2017.12185